Pfizer for Professionals Pfizer for Professionals




Pfizer Medical Information
(Search Medical Responses)
WyethHCP.com
(Access Wyeth for Professionals)
Explore Other Online Resources
ppn-vr-sso-links.htm
To report an adverse event or to speak to a member of Pfizer Medical Information, please call 1-800-438-1985

Share Your Feedback
Prescribing Information
DETROL® LA (tolterodine tartrate) extended release capsules
Overdosage
Return to the DETROL LA Product Center

A 27-month-old child who ingested 5 to 7 tolterodine immediate release tablets 2 mg was treated with a suspension of activated charcoal and was hospitalized overnight with symptoms of dry mouth. The child fully recovered.

Management of Overdosage
Overdosage with DETROL LA Capsules can potentially result in severe central anticholinergic effects and should be treated accordingly.

ECG monitoring is recommended in the event of overdosage. In dogs, changes in the QT interval (slight prolongation of 10% to 20%) were observed at a suprapharmacologic dose of 4.5 mg/kg, which is about 68 times higher than the recommended human dose. In clinical trials of normal volunteers and patients, QT interval prolongation was observed with tolterodine immediate release at doses up to 8 mg (4 mg bid) and higher doses were not evaluated (See PRECAUTIONS, Patients with Congenital or Acquired QT Prolongation).


DETROL LA Safety Information
 

DETROL LA capsules are once daily extended release capsules indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Important Safety Information

DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug or its ingredients.

DETROL LA capsules should be used with caution in patients with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, and significantly reduced hepatic or renal function.

Dry mouth was the most frequently reported adverse event (DETROL LA 23% vs placebo 8%); others (≥4%) included headache (DETROL LA 6% vs placebo 4%), constipation (DETROL LA 6% vs placebo 4%), and abdominal pain (DETROL LA 4% vs placebo 2%).

Download the Full U.S. Prescribing and Patient Information.

SetPProProdListVar.htm
SetPFPGroupVar.htm